<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01304966</url>
  </required_header>
  <id_info>
    <org_study_id>qnischent01</org_study_id>
    <nct_id>NCT01304966</nct_id>
  </id_info>
  <brief_title>Human Papillomatosis Genotyping of Children in Thailand</brief_title>
  <official_title>Human Papillomatosis Genotyping and Severity in Patients With Recurrent Respiratory Papillomatosis of Children in Thailand</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen Sirikit National Institute of Child Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Queen Sirikit National Institute of Child Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present study was to identify risk factors for more severe juvenile
      Recurrent Respiratory Papillomatosis (RRP) through prospective evaluation of a pediatric
      population in Thailand by the employing a protocol that includes staging of disease severity
      using above mentioned staging system at the time of each endoscopic debridement, as well as
      human papilloma virus (HPV) genotyping.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recurrent respiratory papillomatosis is caused by human papilloma virus and is the most
      common benign laryngeal neoplasm in children. Although RRP is rarely fatal, the disease
      requires prolonged, extensive medical and surgical treatment, and causes physical and
      emotional suffering in affected children and their families. Although recurrent respiratory
      papillomatosis is a relatively unusual problem, it accounts for significant health are
      expenditures.The goal of management of RRP is control of the disease, preservation of the
      voice and prevention of major complication .The purpose of study will identify risk factors
      for more severe juvenile RRP through prospective evaluation of a pediatric population in
      Thailand by the employing a protocol that includes staging of disease severity , as well as
      HPV genotyping.

      Objective:

        -  To identify the genotypes of HPV isolated from Thai RRP patients

        -  To compare staging and severity with HPV genotypes

        -  To correlate the following characteristics of the Thai RRP patients with the HPV
           genotypes
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Human Papillomavirus Genotypes</measure>
    <time_frame>12 months</time_frame>
    <description>Distribution of Human papillomavirus(HPV) genotypes identified in the biopsy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cotreta-Derkay Score</measure>
    <time_frame>12 months</time_frame>
    <description>We compared disease severity(Cotreta-Derkay score) between groups of children with two different HPV genotypes
Coltera and Derkay have evolved a staging system to stage recurrent papillomatous lesions involving the respiratory tract.
Coltera-Derkay method of staging :
Clinical score:
Voice: Normal - 0, Abnormal - 1, Aphonia - 2
Stridor: Absent - 0, Present on activity - 1, Present at rest - 2
Respiratory distress - None - 0, Mild - 1, Moderate - 2, Severe - 3, Extreme - 4.
Anatomical score:
For each site - 0 = none, 1=surface lesion, 2= raised lesion, 3=bulky lesion.
Total score = Anatomical score + Total clinical score</description>
  </secondary_outcome>
  <enrollment type="Actual">15</enrollment>
  <condition>Recurrent Laryngeal Papillomatosis</condition>
  <condition>Human Papilloma Virus</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
    <description>excisional biopsy</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Papillomatous tissue samples taken from endoscopic biopsies will be collected by the ENT
      specialists.Samples collected from the subjects will be analyzed for HPV genotype at the Unit
      of virology and molecular, Department of pathology, Faculty of medicine Ramathibodi hospital.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Target enrollment will be all children who are diagnosed with RRP.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients have active laryngeal papillomatosis .

          -  Patients have developed this infection before the age of 18 years old.

        Exclusion Criteria:

          -  Children whose families do not sign an informed consent to enter into study.

          -  Children whose families anticipate discontinuing care at a participating institution
             during the study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pavinee Intakorn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Sirikit National Institute of Child Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pavinee Intakorn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Sirikit National of Child Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Otorhinolaryngology: Queen Sirikit National of Child Health</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Sirikit National Institute of Child Health</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Derkay CS. Task force on recurrent respiratory papillomas. A preliminary report. Arch Otolaryngol Head Neck Surg. 1995 Dec;121(12):1386-91.</citation>
    <PMID>7488368</PMID>
  </reference>
  <reference>
    <citation>Doyle DJ, Gianoli GJ, Espinola T, Miller RH. Recurrent respiratory papillomatosis: juvenile versus adult forms. Laryngoscope. 1994 May;104(5 Pt 1):523-7.</citation>
    <PMID>8189980</PMID>
  </reference>
  <reference>
    <citation>Kashima HK, Shah F, Lyles A, Glackin R, Muhammad N, Turner L, Van Zandt S, Whitt S, Shah K. A comparison of risk factors in juvenile-onset and adult-onset recurrent respiratory papillomatosis. Laryngoscope. 1992 Jan;102(1):9-13.</citation>
    <PMID>1309932</PMID>
  </reference>
  <reference>
    <citation>Rabah R, Lancaster WD, Thomas R, Gregoire L. Human papillomavirus-11-associated recurrent respiratory papillomatosis is more aggressive than human papillomavirus-6-associated disease. Pediatr Dev Pathol. 2001 Jan-Feb;4(1):68-72.</citation>
    <PMID>11200493</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2011</study_first_submitted>
  <study_first_submitted_qc>February 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2011</study_first_posted>
  <results_first_submitted>April 13, 2013</results_first_submitted>
  <results_first_submitted_qc>January 1, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 17, 2014</results_first_posted>
  <last_update_submitted>January 1, 2014</last_update_submitted>
  <last_update_submitted_qc>January 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen Sirikit National Institute of Child Health</investigator_affiliation>
    <investigator_full_name>Pavinee Intakorn</investigator_full_name>
    <investigator_title>department of otorhinolarngology</investigator_title>
  </responsible_party>
  <keyword>RRP</keyword>
  <keyword>HPV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papilloma</mesh_term>
    <mesh_term>Laryngeal Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Date of the recruitment is APril 2011.Number participants staring is fifteen.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Children With Recurrent Respiratory Papillomatosis</title>
          <description>Children hospitalized with recurrent respiratory papillomatosis who underwent biopsy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Children With Recurrent Respiratory Papillomatosis in Thailand</population>
      <group_list>
        <group group_id="B1">
          <title>Children With Recurrent Respiratory Papillomatosis</title>
          <description>Children hospitalized with recurrent respiratory papillomatosis who underwent biopsy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.67" spread="0.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Human Papillomavirus Genotypes</title>
        <description>Distribution of Human papillomavirus(HPV) genotypes identified in the biopsy</description>
        <time_frame>12 months</time_frame>
        <population>We found positive HPV DNA in all children. HPV type 6 and HPV type 11 caused recurrent respiratory papillomatosis in 6 (40%) and 9(60%) of cases,respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Children With Recurrent Respiratory Papillomatosis</title>
            <description>Distribution of Human papillomavirus(HPV) genotypes identified in the biopsy</description>
          </group>
        </group_list>
        <measure>
          <title>Human Papillomavirus Genotypes</title>
          <description>Distribution of Human papillomavirus(HPV) genotypes identified in the biopsy</description>
          <population>We found positive HPV DNA in all children. HPV type 6 and HPV type 11 caused recurrent respiratory papillomatosis in 6 (40%) and 9(60%) of cases,respectively.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV type 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV type 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cotreta-Derkay Score</title>
        <description>We compared disease severity(Cotreta-Derkay score) between groups of children with two different HPV genotypes
Coltera and Derkay have evolved a staging system to stage recurrent papillomatous lesions involving the respiratory tract.
Coltera-Derkay method of staging :
Clinical score:
Voice: Normal - 0, Abnormal - 1, Aphonia - 2
Stridor: Absent - 0, Present on activity - 1, Present at rest - 2
Respiratory distress - None - 0, Mild - 1, Moderate - 2, Severe - 3, Extreme - 4.
Anatomical score:
For each site - 0 = none, 1=surface lesion, 2= raised lesion, 3=bulky lesion.
Total score = Anatomical score + Total clinical score</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HPV 6</title>
            <description>Children with recurrent respiratory papillomatosis from HPV 6</description>
          </group>
          <group group_id="O2">
            <title>HPV 11</title>
            <description>Children with recurrent respiratory papillomatosis from HPV 11</description>
          </group>
        </group_list>
        <measure>
          <title>Cotreta-Derkay Score</title>
          <description>We compared disease severity(Cotreta-Derkay score) between groups of children with two different HPV genotypes
Coltera and Derkay have evolved a staging system to stage recurrent papillomatous lesions involving the respiratory tract.
Coltera-Derkay method of staging :
Clinical score:
Voice: Normal - 0, Abnormal - 1, Aphonia - 2
Stridor: Absent - 0, Present on activity - 1, Present at rest - 2
Respiratory distress - None - 0, Mild - 1, Moderate - 2, Severe - 3, Extreme - 4.
Anatomical score:
For each site - 0 = none, 1=surface lesion, 2= raised lesion, 3=bulky lesion.
Total score = Anatomical score + Total clinical score</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.83" spread="9.94"/>
                    <measurement group_id="O2" value="27.44" spread="8.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <desc>Since this is the observational study, therefore the study process did not pose any risk to the participants (population at risk = 0)</desc>
      <group_list>
        <group group_id="E1">
          <title>Children With Recurrent Respiratory Papillomatosis</title>
          <description>Children hospitalized with recurrent respiratory papillomatosis who underwent biopsy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The number of patients participating in this study was low , so additional studies should be conducted to make the research more effective.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr.Pavinee Intakorn</name_or_title>
      <organization>Queen Sirikit Nation Institute of Thailand</organization>
      <phone>06623548333 ext 2301</phone>
      <email>pintakorn@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

